Literature DB >> 9890944

A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.

S J Siciliano1, S E Kuhmann, Y Weng, N Madani, M S Springer, J E Lineberger, R Danzeisen, M D Miller, M P Kavanaugh, J A DeMartino, D Kabat.   

Abstract

Like the CCR5 chemokine receptors of humans and rhesus macaques, the very homologous (approximately 98-99% identical) CCR5 of African green monkeys (AGMs) avidly binds beta-chemokines and functions as a coreceptor for simian immunodeficiency viruses. However, AGM CCR5 is a weak coreceptor for tested macrophage-tropic (R5) isolates of human immunodeficiency virus type 1 (HIV-1). Correspondingly, gp120 envelope glycoproteins derived from R5 isolates of HIV-1 bind poorly to AGM CCR5. We focused on a unique extracellular amino acid substitution at the juncture of transmembrane helix 4 (TM4) and extracellular loop 2 (ECL2) (Arg for Gly at amino acid 163 (G163R)) as the likely source of the weak R5 gp120 binding and HIV-1 coreceptor properties of AGM CCR5. Accordingly, a G163R mutant of human CCR5 was severely attenuated in its ability to bind R5 gp120s and to mediate infection by R5 HIV-1 isolates. Conversely, the R163G mutant of AGM CCR5 was substantially strengthened as a coreceptor for HIV-1 and had improved R5 gp120 binding affinity relative to the wild-type AGM CCR5. These substitutions at amino acid position 163 had no effect on chemokine binding or signal transduction, suggesting the absence of structural alterations. The 2D7 monoclonal antibody has been reported to bind to ECL2 and to block HIV-1 binding and infection. Whereas 2D7 antibody binding to CCR5 was unaffected by the G163R mutation, it was prevented by a conservative ECL2 substitution (K171R), shared between rhesus and AGM CCR5s. Thus, it appears that the 2D7 antibody binds to an epitope that includes Lys-171 and may block HIV-1 infection mediated by CCR5 by occluding an HIV-1-binding site in the vicinity of Gly-163. In summary, our results identify a site for gp120 interaction that is critical for R5 isolates of HIV-1 in the central core of human CCR5, and we propose that this site collaborates with a previously identified region in the CCR5 amino terminus to enable gp120 binding and HIV-1 infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9890944     DOI: 10.1074/jbc.274.4.1905

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

3.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

4.  Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

Authors:  Kenji Maeda; Debananda Das; Philip D Yin; Kiyoto Tsuchiya; Hiromi Ogata-Aoki; Hirotomo Nakata; Rachael B Norman; Lauren A Hackney; Yoshikazu Takaoka; Hiroaki Mitsuya
Journal:  J Mol Biol       Date:  2008-06-20       Impact factor: 5.469

5.  Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.

Authors:  E J Platt; S E Kuhmann; P P Rose; D Kabat
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 6.  Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases.

Authors:  Won-Tak Choi; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2011-05-12

7.  Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

Review 8.  Polyvalent AIDS vaccines.

Authors:  Shan Lu; Jill M Grimes Serrano; Shixia Wang
Journal:  Curr HIV Res       Date:  2010-12       Impact factor: 1.581

9.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.